Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Change in Acquisitions & Divestments: 2020-2024

Historic Change in Acquisitions & Divestments for Xeris Biopharma Holdings (XERS) over the last 4 years, with Dec 2024 value amounting to $10.2 million.

  • Xeris Biopharma Holdings' Change in Acquisitions & Divestments fell 31.76% to $10.2 million in Q4 2024 from the same period last year, while for Dec 2024 it was $40.2 million, marking a year-over-year decrease of 18.39%. This contributed to the annual value of $40.2 million for FY2024, which is 0.59% up from last year.
  • Xeris Biopharma Holdings' Change in Acquisitions & Divestments amounted to $10.2 million in Q4 2024, which was down 31.76% from $15.0 million recorded in Q3 2024.
  • In the past 5 years, Xeris Biopharma Holdings' Change in Acquisitions & Divestments ranged from a high of $34.6 million in Q1 2021 and a low of $5.0 million during Q1 2024.
  • Over the past 3 years, Xeris Biopharma Holdings' median Change in Acquisitions & Divestments value was $10.0 million (recorded in 2024), while the average stood at $10.5 million.
  • In the last 5 years, Xeris Biopharma Holdings' Change in Acquisitions & Divestments tumbled by 80.66% in 2022 and then surged by 117.86% in 2023.
  • Quarterly analysis of 5 years shows Xeris Biopharma Holdings' Change in Acquisitions & Divestments stood at $17.8 million in 2020, then slumped by 41.14% to $10.5 million in 2021, then fell by 11.43% to $9.3 million in 2022, then surged by 61.29% to $15.0 million in 2023, then slumped by 31.76% to $10.2 million in 2024.
  • Its last three reported values are $10.2 million in Q4 2024, $15.0 million for Q3 2024, and $10.0 million during Q2 2024.